# US 2016/0355565 A1 · Diagnosis of a neuroautoimmune disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355565 A1
- Document ID: US20160355565A1
- Status: Published application
- Kind: A1
- Application number: 15/172,450
- Filed: 2016-06-03
- Published: 2016-12-08
- Earliest claimed: 2015-06-04
- Assignees: EUROIMMUN Medizinische Labordiagnostika AG
- Applicants: Euroimmun Medizinische Labordiagnostika AG
- Inventors: Winfried STOECKER; Lars Komorowski; Madeleine Scharf; Ramona Miske; Yvonne Denno; Inga-Madeleine Dettmann; Christian Probst; Stefanie Hahn; Stephanie Kade; George Trendelenburg
- Web page: https://patentgrep.com/patent/US20160355565A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/4713: {Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/564: for pre-existing immune complex or autoimmune disease {, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9}
- G01N 33/6854: {Immunoglobulins}
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07B 2200/11: Compounds covalently bound to a solid support
- C07K 2317/20: characterized by taxonomic origin
- G01N 2333/47: Assays involving proteins of known structure or function as defined in the subgroups
- G01N 2800/16: Ophthalmology
- G01N 2800/28: Neurological disorders
- G01N 2800/285: Demyelinating diseases; Multipel sclerosis
- G01N 2800/7095: Inflammation
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07B: GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR (preparation of carboxylic acid esters by telomerisation C07C67/47; telomerisation C08F)

## Abstract

A method for diagnosing a disease by detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample, a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which may be immobilized, a method of treating a disease by applying to a subject the polypeptide that binds to an autoantibody, an autoantibody binding to flotillin1 and/or flotillin2, a method for isolating the autoantibody, a pharmaceutical composition, a medical device and test kit comprising the polypeptide, are provided. A method for detecting the presence of an autoantibody is also provided.

## Claims

### Claim 1

A method for diagnosing a disease comprising detecting an autoantibody that binds to flotillin1 and/or flotillin2 in a sample from a patient.

### Claim 2

A polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which is immobilized on a solid carrier.

### Claim 3 (depends on 1)

The method of claim 1, wherein the detecting comprises applying to the sample a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof that binds to the autoantibody.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has or the disease is associated with one or more symptoms selected from the group consisting of elevated cell number in CSF, intrathecal IgG synthesis, oligoclonal bands in CSF, MRZ reaction in CSF, impairment of vision, optic neuritis, headache, spinal cord lesions, and brain lesions.

### Claim 5 (depends on 4)

The method of claim 4, wherein the impairment of vision is visual acuity.

### Claim 6 (depends on 1)

The method of claim 1, wherein the disease is a neurological disease.

### Claim 7 (depends on 6)

The method of claim 6, wherein the neurological disease is a demyelinating disease, CNS, encephalon, or a disease associated with inflammation of the optical nerve.

### Claim 8 (depends on 1)

The method of claim 1, wherein the polypeptide is provided in the form of a cell comprising a nucleic acid encoding said polypeptide or in the form of a tissue comprising said polypeptide.

### Claim 9 (depends on 1)

The method of claim 1, wherein the sample is a bodily fluid comprising the autoantibodies, and wherein the bodily fluid is selected from the group consisting of whole-blood, serum, cerebrospinal fluid, and saliva.

### Claim 10 (depends on 1)

The method of claim 1, comprising applying to the sample a polypeptide comprising flotillin1 or a variant thereof and a polypeptide comprising flotillin2 or a variant thereof, and wherein the polypeptide comprising flotillin1 or a variant thereof and the polypeptide comprising flotillin2 or a variant thereof are present as a part of a complex.

### Claim 11 (depends on 1)

The method of claim 1, wherein the autoantibody binds to a complex comprising flotillin1 and flotillin2.

### Claim 12 (depends on 2)

A method of treating a disease, comprising applying the polypeptide according to claim 2 that binds an autoantibody binding to flotillin1 and/or flotillin2 to a subject in need thereof.

### Claim 13

An isolated autoantibody that binds to flotillin1 and/or flotillin2.

### Claim 14 (depends on 2)

A method for isolating an autoantibody that binds to flotillin1 and/or flotillin2, the method comprising:
a) contacting a sample comprising the autoantibody with the polypeptide according to claim 2 under conditions compatible with formation of a complex, wherein said autoantibody binds to said polypeptide,
b) isolating the complex formed in step a),
c) dissociating the complex isolated in step b), and
d) separating the autoantibody from the polypeptide.

### Claim 15 (depends on 2)

A pharmaceutical composition comprising the polypeptide of claim 2 and an acceptable pharmaceutical carrier.

### Claim 16 (depends on 2)

A test kit for diagnosis of a disease, comprising the polypeptide of claim 2 and a means for detecting a complex comprising the polypeptide and an autoantibody that binds to flotillin1 and/or flotillin2.

### Claim 17 (depends on 13)

The isolated autoantibody of claim 13, wherein the autoantibody is in complex with a polypeptide comprising flotillin1 and/or flotillin2 or a variant thereof, which is immobilized on a solid carrier.

### Claim 18

A method for detecting the presence of an autoantibody, comprising:
exposing a polypeptide comprising at least one of flotillin1 and flotillin2 or a variant thereof, which is immobilized on a solid carrier, to a sample from a subject and
detecting the autoantibody which has bound to the polypeptide.

### Claim 19 (depends on 12)

The method of treating a disease of claim 12, wherein the subject is a human.

### Claim 20 (depends on 2)

The polypeptide of claim 2, comprising the amino acid sequence of SEQ ID NO: 2, 4, 6, and/or 8 or comprising an amino acid sequence encoded by the nucleotide sequence of SEQ ID NO: 1, 3, 5, and/or 7.
